Status:
COMPLETED
Zoladex® 10.8 BC RWS
Lead Sponsor:
AstraZeneca
Conditions:
Breast Cancer
Eligibility:
FEMALE
18+ years
Brief Summary
This is a multi-center, retrospective-prospective, observational, active-control, non-inferiority, real world study using hospital medical record data, with objectives to evaluate E2 suppressive effec...
Eligibility Criteria
Inclusion
- Inclusion Criteria
- Diagnosed with primary breast cancer
- Female, ≥18 years old (at index date)
- HR positive
- Receive Zoladex® 10.8 mg or Zoladex® 3.6 mg treatment
- Premenopausal status prior to the treatment of Zoladex®. Baseline premenopausal status will be confirmed if the patient's last E2 measurement within 180 days prior to the index date indicated premenopausal status or there was a recorded menstrual history within 180 days prior to the index date
- At least one actual or expected E2 testing measurement within 8-28 weeks of the index date Exclusion Criteria
- Patients received concurrent treatments that may affect E2 testing results
Exclusion
Key Trial Info
Start Date :
January 6 2022
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
December 15 2023
Estimated Enrollment :
1176 Patients enrolled
Trial Details
Trial ID
NCT05184257
Start Date
January 6 2022
End Date
December 15 2023
Last Update
January 23 2025
Active Locations (16)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Beijing, China, 100021
2
Research Site
Changsha, China, 410013
3
Research Site
Chengdu, China
4
Research Site
Guangan, China